Jean-claude Eisenmann

Mulhouse, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Splenectomy in β-thalassemia patients: Practices and risks in a nationwide study.

Splenectomy in β-thalassemia patients: Practices and risks in a nationwide study.

Journal: HemaSphere
Published: November 26, 2025

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.

Journal: Blood
Published: November 01, 2021

Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study.

Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study.

Journal: Blood advances
Published: March 30, 2020

Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up.

Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up.

Journal: Blood cancer journal
Published: March 15, 2020

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.

Journal: British journal of haematology
Published: April 02, 2019

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 06, 2018

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.

Journal: Blood
Published: July 14, 2018

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.

Journal: Blood
Published: January 16, 2016

Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate.

Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: January 17, 2015

Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.

Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.

Journal: Haematologica
Published: November 14, 2014

Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia.

Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia.

Journal: British journal of haematology
Published: December 08, 2013
Showing 1-11 of 11

Last Updated: 09/26/2026